Market Overview

LifeMax Acquires Worldwide Right to Clinical Stage Orphan Asset


LifeMax Laboratories, Inc. ("LifeMax"), a private company focused on
treating diseases with few or no therapeutic options, today announced an
exclusive worldwide license from Novartis Pharma AG for the right to
develop, manufacture and commercialize BPR277, a clinical stage asset
with positive clinical proof of concept for the treatment of Netherton

Netherton Syndrome is an autosomal recessive monogenic disease caused by
mutations in the SPINK5 gene that encodes a serine peptidase inhibitor.
Symptoms affect the skin, hair and immune systems. Netherton Syndrome in
newborns can lead to failure to thrive and can be life-threatening.
Currently there are no FDA approved products, and treatment is limited
to symptom relief with unproven efficacy and unwanted side effects.
Netherton Syndrome is a rare condition with an estimated prevalence of
1-9 per 1,000,000.

"We are very excited to enter into this licensing agreement with
Novartis and are committed to continuing the development of BPR277 which
fits well with our corporate strategy of developing drugs for diseases
with few or no therapeutic options. This relationship is a testament to
our drug development capability and expertise. We look forward to
bringing this much needed therapy to people with Netherton Syndrome, and
potentially other diseases with skin barrier impairment," said Larry
Hsu, LifeMax's Co-founder and CEO, an industry veteran who previously
founded and built Impax Laboratories into a publicly traded
multi-billion dollar company.

Under the terms of the licensing agreement, Novartis will, among others,
receive an upfront payment, development and regulatory milestones as
well as royalty on net sales.

About LifeMax Laboratories Inc.

LifeMax Laboratories, Inc. (,
a wholly-owned subsidiary of LifeMax Healthcare International
Corporation (,
is a clinical-stage biotech company focused on treating diseases with
few or no therapeutic options. LifeMax is applying its expertise and
in-depth experience with drug development and commercialization to
advance its well-balanced portfolio of products addressing critical
unmet medical needs. It has recently closed a Series A round of $25

View Comments and Join the Discussion!